Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...

Median PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...